Advancing Atrial Fibrillation Therapy

Healium Medical develops no-contact guided ablation system for treatment of atrial fibrillation – the most common cardiac arrhythmia affecting more than 46.1 Million patients worldwide. 

The company develops transcatheter ultrasound technology enabling rapid, no-contact circumferential 

pulmonary vein isolation with real-time lesion monitoring.  Our goal is to improve procedure efficacy 

simplify procedure flow and shorten procedure time.

The company operates out of Yokneam, Israel, have full scale in-house R&D lab, employs multidisciplinary team of physicist, engineers & physicians and have pre-clinical data supporting the feasibility of its proprietary technology. 

Description of Atrial Fibrillation:

Atrial fibrillation (AF or Afib for short) is the most

common cardiac arrhythmia or rhythm abnormality.

AF is an irregular and often rapid heart rate that may cause symptoms like heart palpitations, fatigue, and shortness of breath.  AF occurs when the upper chambers of the heart (atria) beat rapidly and irregularly (fibrillate). This can cause blood to pool and form clots in an area of the heart called the left atrial appendage (LAA).

When a blood clot escapes from the LAA and travels

to another part of the body, it can cause a stroke. 

These who have AF X5 times more likely to suffer a stroke than someone with a regular heartbeat.

Fortunately, AF may be treated with medication, cardioversion or a catheter ablation procedure.  However, Despite the large number of advances in the field over the past two decades, AF remains a substantial cause of mortality and morbidity


Normal Heart

Atrial Fibrillation Heart

5x Risk of Stroke

for patients with AF 

Heart fibrillations

lead to blood

clots formation

90% of trigers found in the pul-monary vein

blood clot​

Catheter Ablation | Cornerstone of AF Treatment

Procedure Goal

Electrical isolation of the

four pulmonary veins​

Procedure Description

Ablation catheters create lesions around the pulmonary veins to block electrical triggers



Full Thickness

Full Circle

No Gaps

Clinical Need

Poor / No

tissue contact


between lesions

No lesion monitoring lesions

Close to 40% of patients will required 2nd procedure over

time due to key technological limitations of existing approved products.

Market Potential


Sales/year 2015


Existing Market



of the diagnosed symptomatic AF patient  population

receiving ablation


Newly diagnosed

per yearin the US alone 


Patients worldwide



11% CAGR

2013 - 2016


M&A Since 2008 

Contact us


Tel: +972-73-3201055 

Thanks! Message sent.